about
Exclusion Criteria in National Health State Valuation Studies: A Systematic Review.Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5LSocial participation in patients with multiple sclerosis: correlations between disability and economic burden.The association between asthma control, health care costs, and quality of life in France and SpainComparing EQ-5D valuation studies: a systematic review and methodological reporting checklist.Results from an exploratory study to test the performance of EQ-5D-3L valuation subsets based on orthogonal designs, and an investigation into some modeling and transformation alternatives for the utility function.Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal PerspectiveImpact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancerTherapeutic management of complex anal fistulas by installing a nitinol closure clip: study protocol of a multicentric randomised controlled trial--FISCLOSE.Lead versus lag-time trade-off variants: does it make any difference?EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes.Using surveys to calculate disability-adjusted life-year.Randomised, prospective, medico-economic nationwide French study of islet transplantation in patients with severely unstable type 1 diabetes: the STABILOT study protocol.A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.Sample size determination for EQ-5D-5L value set studies.Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size.New insights into the burden and costs of multiple sclerosis in Europe: Results for France.Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.What matters most? Evidence-based findings of health dimensions affecting the societal preferences for EQ-5D health states.Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolismEvaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France.Development of an EORTC-8D utility algorithm for Sri Lanka.SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.Optimal threshold estimator of a prognostic marker by maximizing a time-dependent expected utility function for a patient-centered stratified medicine.Differences between hypothetical and experience-based value sets for EQ-5D used in Sweden: Implications for decision makers.Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?The impact of low back pain on health-related quality of life in old age: results from a survey of a large sample of Swiss elders living in the community.Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.EQ-5D Portuguese population norms.The valuation of the EQ-5D in Portugal.Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.Economic Evaluation of Pneumococcal Vaccines for Adults Aged Over 50 Years in Belgium.Impact of asthma on women and men: Comparison with the general population using the EQ-5D-5L questionnaire
P2860
Q30252110-49FA0D83-31B3-46D5-B443-3047EEF4B056Q33616369-53B98250-4951-4A5C-B270-CE668CF3BC68Q33729957-93F14837-B61F-4E12-867B-FEA322BBC7F1Q34630944-DE10A003-9751-487A-9FC3-9190FD602389Q34633630-F091D2CD-875D-47E8-B7C2-08874834E67FQ35851066-7039EC52-B59B-44EE-B4BF-FD08AA65E8E2Q35923254-B96BB97D-1B8B-411A-AFB3-B1E7C3675DDCQ35961279-FD25FFE3-243A-4C45-929E-D649ACFD7870Q36394607-68AA8261-9BBE-4826-B551-673DD93EC6E1Q36406047-7A5EEE88-6203-4923-A390-92D86DB1621DQ37057633-BBBF10A8-B90E-4F09-A108-1A06BFCFDA5DQ37256597-F740C819-CE12-42D2-8953-59F07F336D61Q37537391-03036F94-43AE-4A79-A3A9-C5B31EE028BAQ37681247-35ACB7EB-ED5E-4387-8B76-65EDE7062635Q38598931-68FAD098-B2BC-4FD0-89A5-7DDF0A18843AQ38616456-8C4BE0D0-FB98-402C-8AE7-524968B68B2DQ38617304-3DF5B680-B795-4C4E-B009-88D35D19A456Q38667683-998EB9D1-6B63-4679-A9F9-FEC836F576D3Q39108852-E460EA82-3543-4A3D-A58A-F1BC6213FA68Q39855919-B84B3C18-478F-44D2-AFF1-51E89385E355Q40235378-FA9F9820-E350-4ACE-8757-CF47C6AC69C1Q40402410-1B311949-65DD-4D1B-A542-4B6021BC67ECQ40688211-02C74B78-D599-4E44-A9E3-A21A7F665D8AQ40900632-129BE288-0190-4F18-A4D5-433F3DAF55DDQ42283151-9140CB27-EA83-47CC-B3E9-590BB3A91DF2Q43604978-9FBA8628-BB1A-4BB1-9F44-CA92C7611691Q44572362-C802FEC3-4B16-4132-A17B-E2C31D516C89Q47549752-1D36CD8A-B850-4CDE-AD6D-426EEBBB3549Q47935399-4AF35F2D-ACAB-408F-BAB5-FFFDC591ACE5Q47989102-E0F62F03-D02F-48A4-BC14-347DEEE5672EQ48081904-619EA280-1B20-4A70-8A51-A629F5C0FE20Q48106673-B9D5CB53-EB4B-46FB-A2A9-ED477FFBEDDCQ48113484-47E1E6B5-5264-4AEA-9389-5ABD8F2F3B75Q48193726-DA5553DB-A3E3-4E65-A79A-080ABF8108D7Q48228665-A5EFE7BA-4405-425D-9CF9-93705C3D248AQ49477401-9ED9097A-5515-4986-937D-3C7088D3883CQ50116116-66242AA6-F850-4242-B5B4-2980E81BB3F4Q58715354-5707347F-6CC0-4FC7-BFD9-9B0CB3BFE089
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Valuing EQ-5D using time trade-off in France.
@en
Valuing EQ-5D using time trade-off in France.
@nl
type
label
Valuing EQ-5D using time trade-off in France.
@en
Valuing EQ-5D using time trade-off in France.
@nl
prefLabel
Valuing EQ-5D using time trade-off in France.
@en
Valuing EQ-5D using time trade-off in France.
@nl
P2860
P1476
Valuing EQ-5D using time trade-off in France.
@en
P2093
Gérard de Pouvourville
Julie Chevalier
P2860
P2888
P356
10.1007/S10198-011-0351-X
P577
2011-09-21T00:00:00Z
P6179
1045435800